Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: A pharmacologic dilemma on hepatocyte proliferation

Parlakgumus A., Colakoglu T., Kayaselcuk F., Colakoglu S., Ezer A., Caliskan K., ...Daha Fazla

JOURNAL OF SURGICAL RESEARCH, cilt.179, sa.1, ss.60-65, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 179 Sayı: 1
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/j.jss.2012.08.046
  • Dergi Adı: JOURNAL OF SURGICAL RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.60-65
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background: There is a strong relationship between liver regeneration and angiogenesis and fibrosis. It is known that Spironolactone, an aldosterone antagonist, acting on rennin ealdosterone axis, and Losartan, an angiotensin II type I antagonist, have both antifibrotic and antiangiogenic effects. Theoretically, the end result of these mechanisms with contradictory influences on liver regeneration is not known well. In this study, we aimed to reveal the effects on liver regeneration of administration of Spironolactone and Losartan, having contradicting effects on regeneration through antiangiogenesis and antifibrosis.